Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone Hemisuccinate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.78 |
| ▸ | PGR | P06401 | 5/20 | 0.78 |
| ▸ | AR | P10275 | 3/20 | 0.78 |
| ▸ | F2 | P00734 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | IL6 | P05231 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone Hemisuccinate SCHEMBL1169509 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL10953512 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL18321784 | 0.97 | NR3C1 (0.81) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL1030222 | 0.96 | NR3C1 (0.79) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL5525022 | 0.93 | NR3C1 (0.74) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL7915 | 0.92 | NR3C1 (1.00) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL2482645 | 0.92 | NR3C1 (1.00) | NR3C1CYP3A4PGRARF2 | |
| SCHEMBL11329958 | 0.92 | NR3C1 (0.82) | NR3C1CYP3A4PGRARF2 | |
| SCHEMBL11201742 | 0.92 | NR3C1 (0.82) | NR3C1CYP3A4PGRARF2 | |
| Methylprednisolone Hemisuccinate SCHEMBL29053159 | 0.92 | NR3C1 (0.98) | NR3C1CYP3A4PGRARF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12186 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005818-A | Application of miR-144 inhibitor in preparation of medicine for enhancing curative effect of glucocorticoid on ARDS and composition thereof | 胜利油田中心医院 | 2026-05-12 | — | — | CN | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3820479-B1 | METHODS TO REDUCE COMPLICATIONS OF INTRA-ARTICULAR STEROID | TAIWAN LIPOSOME CO LTD (TW) | 2026-03-11 | — | — | EP | claimed |
| US-12472069-B2 | Methods for sacroiliac joint stabilization | Tenon Medical, Inc. (US) | 2025-11-18 | — | — | US | claimed |
| EP-4646441-A1 | ANTI-IL-11R ALPHA ANTIBODIES FOR TREATING THYROID EYE DISEASE | Lassen Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| EP-4567037-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND IN TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-11 | — | — | EP | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |
| EP-0740528-A4 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP (US) | 1998-04-01 | — | — | EP | claimed |
| US-5733572-A | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles | IMARX PHARMACEUTICAL CORP. (US) | 1998-03-31 | — | — | US | claimed |
| WO-1997020578-A1 | NON-PRESERVED TOPICAL CORTICOSTEROID FOR TREATMENT OF DRY EYE, FILAMENTARY KERATITIS, AND DELAYED TEAR CLEARANCE | UNIVERSITY OF MIAMI (US) | 1997-06-12 | — | — | WO | claimed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | claimed |
| CN-1137748-A | Gas used as local and subcutaneous transmission carrier and microspheres filled with gas precursor | IMARX PHARMACEUTICAL CORP (US) | 1996-12-11 | — | — | CN | claimed |
| EP-0740528-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1996-11-06 | — | — | EP | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
| US-4406883-A | SHAPES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-09-27 | — | — | US | claimed |
| US-4292300-A | METHYL CELLULOSE, WATER, DRUG | INVERESK RESEARCH INTERNATIONAL (GB) | 1981-09-29 | — | — | US | claimed |